Goldman Sachs Analyst thinks otherwise. The company behind the Hepatitis C cure seems to also not doing well with monetizing their cure. There are also countries like Brazil that just suspended the patent.

https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patie...